Defne Yarar
Defne Yarar
Verified email at merrimackpharma.com
Title
Cited by
Cited by
Year
A dynamic actin cytoskeleton functions at multiple stages of clathrin-mediated endocytosis
D Yarar, CM Waterman-Storer, SL Schmid
Molecular biology of the cell 16 (2), 964-975, 2005
4682005
Cargo and dynamin regulate clathrin-coated pit maturation
D Loerke, M Mettlen, D Yarar, K Jaqaman, H Jaqaman, G Danuser, ...
PLoS biology 7 (3), e1000057, 2009
3932009
The Wiskott–Aldrich syndrome protein directs actin-based motility by stimulating actin nucleation with the Arp2/3 complex
D Yarar, W To, A Abo, MD Welch
Current Biology 9 (10), 555-S1, 1999
3471999
Formation of filopodia-like bundles in vitro from a dendritic network
D Vignjevic, D Yarar, MD Welch, J Peloquin, T Svitkina, GG Borisy
Journal of Cell Biology 160 (6), 951-962, 2003
2872003
Nuclear Pore Complex Number and Distribution throughout theSaccharomyces cerevisiae Cell Cycle by Three-Dimensional Reconstruction from Electron …
M Winey, D Yarar, TH Giddings Jr, DN Mastronarde
Molecular biology of the cell 8 (11), 2119-2132, 1997
2421997
SNX9 regulates dynamin assembly and is required for efficient clathrin-mediated endocytosis
F Soulet, D Yarar, M Leonard, SL Schmid
Molecular biology of the cell 16 (4), 2058-2067, 2005
2282005
SNX9 couples actin assembly to phosphoinositide signals and is required for membrane remodeling during endocytosis
D Yarar, CM Waterman-Storer, SL Schmid
Developmental cell 13 (1), 43-56, 2007
2072007
Cargo-and adaptor-specific mechanisms regulate clathrin-mediated endocytosis
M Mettlen, D Loerke, D Yarar, G Danuser, SL Schmid
Journal of Cell Biology 188 (6), 919-933, 2010
1632010
The type III effector EspF coordinates membrane trafficking by the spatiotemporal activation of two eukaryotic signaling pathways
NM Alto, AW Weflen, MJ Rardin, D Yarar, CS Lazar, R Tonikian, A Koller, ...
Journal of Cell Biology 178 (7), 1265-1278, 2007
1472007
SNX9 activities are regulated by multiple phosphoinositides through both PX and BAR domains
D Yarar, MC Surka, MC Leonard, SL Schmid
Traffic 9 (1), 133-146, 2008
1182008
Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors
DC Kirouac, JY Du, J Lahdenranta, R Overland, D Yarar, V Paragas, ...
Science signaling 6 (288), ra68-ra68, 2013
1062013
An assembly-incompetent mutant establishes a requirement for dynamin self-assembly in clathrin-mediated endocytosis in vivo
BD Song, D Yarar, SL Schmid
Molecular biology of the cell 15 (5), 2243-2252, 2004
832004
Motility determinants in WASP family proteins
D Yarar, JA D'Alessio, RL Jeng, MD Welch
Molecular biology of the cell 13 (11), 4045-4059, 2002
712002
Differential requirements for clathrin-dependent endocytosis at sites of cell–substrate adhesion
EM Batchelder, D Yarar
Molecular biology of the cell 21 (17), 3070-3079, 2010
572010
Kinetochore genes are coordinately up-regulated in human tumors as part of a FoxM1-related cell division program
P Thiru, DM Kern, KL McKinley, JK Monda, F Rago, KC Su, T Tsinman, ...
Molecular biology of the cell 25 (13), 1983-1994, 2014
512014
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)
B Schoeberl, A Kudla, K Masson, A Kalra, M Curley, G Finn, E Pace, ...
NPJ systems biology and applications 3 (1), 1-17, 2017
452017
Signal analysis of total internal reflection fluorescent speckle microscopy (TIR‐FSM) and wide‐field epi‐fluorescence FSM of the actin cytoskeleton and focal adhesions in …
MC Adams, A Matov, D Yarar, SL Gupton, G Danuser, ...
Journal of microscopy 216 (2), 138-152, 2004
402004
Event ordering in live-cell imaging determined from temporal cross-correlation asymmetry
DR Sisan, D Yarar, CM Waterman, JS Urbach
Biophysical journal 98 (11), 2432-2441, 2010
112010
Heregulin–ErbB3-driven tumor growth persists in PI3 kinase mutant cancer cells
D Yarar, J Lahdenranta, W Kubasek, UB Nielsen, G MacBeath
Molecular cancer therapeutics 14 (9), 2072-2080, 2015
92015
Model‐based design of a decision tree for treating HER2+ cancers based on genetic and protein biomarkers
DC Kirouac, J Lahdenranta, J Du, D Yarar, MD Onsum, UB Nielsen, ...
CPT: pharmacometrics & systems pharmacology 4 (3), 212-220, 2015
72015
The system can't perform the operation now. Try again later.
Articles 1–20